Science, medicine, and the future: Pathogenesis of sepsis: new concepts and implications for future treatment
- 1 February 2003
- Vol. 326 (7383) , 262-266
- https://doi.org/10.1136/bmj.326.7383.262
Abstract
Severe sepsis and septic shock are important causes of death in intensive care units. Although our understanding of the pathogenesis of inflammation and sepsis has improved, until recently this has not translated into clinical benefit. Several new treatment approaches have given encouraging results. Evidence suggests that the way forward is to develop pathogen specific regimens rather than assume that one treatment fits all. #### Summary points Bacterial cell walls, endotoxins, and exotoxins are powerful activators of innate and acquired immune responses Molecules expressed by pathogens interact with Toll-like receptors on immune cells, activating the immune response Cytokines are important in the pathogenesis of sepsis Susceptibility to sepsis may be due to inherited or acquired mutations of innate immune genes Severe sepsis and septic shock are clinical manifestations of a dysregulated immune response to invasive pathogens Adjunctive therapy with low dose steroids, activated protein C or early supportive care can reduce mortality from severe sepsis and septic shock Pathogen recognition receptors (such as Toll-like receptors) and mediators of sepsis (such as macrophage migration inhibitory factor) might be novel targets for treatment We selected articles for this review by searching Medline using the keywords sepsis, therapy, and Toll-like receptors. We concentrated on publications on the pathogenesis of sepsis and treatment of septic shock. As the number of references that could be cited was limited, we have often referenced review articles rather than original publications. Severe sepsis and septic shock are life threatening complications of infections and the most common cause of death in intensive care units. However, a lack of widely accepted definitions of these complications has made it difficult to obtain accurate estimates of their frequency. A study published by the Centers for Disease Control in the United States indicated that the incidence of septicaemia had increased from 73.6 per 100 000 patients in …Keywords
This publication has 31 references indexed in Scilit:
- Essential role of MD-2 in LPS responsiveness and TLR4 distributionNature Immunology, 2002
- Clinical Trials of Immunomodulatory Therapies in Severe Sepsis and Septic ShockClinical Infectious Diseases, 2002
- Innate Immune RecognitionAnnual Review of Immunology, 2002
- Drosophila innate immunity: an evolutionary perspectiveNature Immunology, 2002
- MIF regulates innate immune responses through modulation of Toll-like receptor 4Nature, 2001
- Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic ShockNew England Journal of Medicine, 2001
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001
- Microbiologic Findings and Correlations with Serum Tumor Necrosis Factor–α in Patients with Severe Sepsis and Septic ShockThe Journal of Infectious Diseases, 1999
- MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemiaNature, 1993
- Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection.The Journal of Experimental Medicine, 1989